Saturday 17 October 2026
Export ADAG’s income statement to Excel — free account
Adagene Inc. Sponsored ADR
ADAG Healthcare Biotechnology
Adagene Inc. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $7.7 million, up 7,333.0% from fiscal 2024. Insiders bought in the last twelve months.
2.06
0.34
−14.17%
Follow ADAG
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 2 | 3 | 2 | 4 | — | — | — |
P/E ratio |
— | — | — | — | — | 0.00 | 0.00 | — |
Altman Z-Score |
(4.64) | (4.15) | (1.91) | (2.89) | 4.34 | — | — | — |
P/S ratio |
— | — | — | — | — | 0.00 | 0.00 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(10.30) | (9.06) | (2.91) | (3.92) | 4.75 | (3.17) | 2.46 | — |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Beneish M-Score |
61.98 | (23.62) | (1.47) | (3.11) | 11.37 | 13.17 | — | — |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
1.04 | 0.60 | 0.67 | 0.91 | 0.00 | 0.00 | 0.00 | — |
EV/FCF |
1.04 | 0.59 | 0.65 | 0.89 | 0.00 | 0.00 | 0.00 | — |
Quick Ratio |
2.96 | 2.23 | 3.50 | 2.62 | 6.10 | 4.66 | 14.27 | — |
Current Ratio |
3.07 | 2.30 | 3.61 | 2.71 | 6.24 | 4.90 | 14.47 | — |
Net Debt/EBITDA |
3.46 | 2.04 | 4.06 | 1.53 | 2.39 | 1.68 | 5.39 | — |
Debt/Assets |
2.36% | 14.94% | 15.30% | 11.15% | 2.30% | 4.92% | 1.74% | 0.00% |
Debt/Equity |
0.05 | 0.26 | 0.25 | 0.20 | 0.03 | (0.05) | (0.03) | — |
Asset Turnover |
0.09 | 0.00 | 0.14 | 0.05 | 0.07 | 0.01 | 0.01 | — |
Operating CF/Net income |
0.89 | 0.89 | 1.50 | 0.61 | 0.59 | 0.67 | 1.71 | — |
Capex/Depreciation |
(0.04) | (0.05) | (0.08) | (0.60) | (2.23) | (1.08) | (1.08) | — |
Interest Coverage |
(46.29) | (42.20) | (21.41) | (121.05) | (198.91) | (213.41) | (138.81) | — |
| (41.01%) | (55.21%) | (24.66%) | (66.74%) | (217.98%) | 58.26% | 22.78% | — | |
| (21.02%) | (32.61%) | (14.13%) | (46.78%) | (53.48%) | (44.85%) | (31.50%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(33.28%) | (65.90%) | (22.60%) | (82.43%) | (45.86%) | (65.59%) | (16.91%) | — |
Average Days of Receivables |
0.82 | 29.36 | 4.47 | 24.33 | 269.27 | 68.95 | 1,454.83 | — |
Research and Development Expense of Revenue |
287.24% | 27,888.95% | 202.30% | 875.31% | 669.26% | 4,784.99% | 3,377.46% | — |
Selling, General and Administrative Expense of Revenue |
92.24% | 7,047.77% | 47.89% | 127.78% | 141.91% | 1,471.61% | 716.23% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
48.78% | 4,757.36% | 40.15% | 113.21% | 183.58% | 1,445.21% | 2,110.31% | — |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
— | — | — | — | — | (8.90%) | (8.90%) | — |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Revenue per Share |
0.16 | 0.00 | 0.41 | 0.21 | 0.25 | 0.05 | 0.04 | — |
Operating CF per Share |
(0.33) | (0.66) | (0.65) | (1.12) | (1.08) | (2.24) | (2.35) | — |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.02) | (0.06) | (0.07) | (0.08) | — |
Free Cash Flow per Share |
(0.33) | (0.66) | (0.65) | (1.14) | (1.15) | (2.31) | (2.43) | — |
Cash per Share |
1.58 | 1.89 | 2.51 | 3.32 | 4.36 | 5.89 | 8.28 | — |
Shareholders Equity per Share |
0.75 | 1.12 | 1.61 | 1.92 | 3.91 | (7.00) | (4.69) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.75 | 1.12 | 1.61 | 1.92 | 3.91 | (7.00) | (4.69) | — |
Free Cash Flow |
(15.67) | (29.73) | (28.53) | (49.30) | (45.92) | (29.46) | (29.46) | — |
Working Capital |
52.20 | 49.59 | 81.99 | 94.24 | 156.13 | 62.95 | 96.74 | — |
Capital Expenditures |
(0.02) | (0.03) | (0.08) | (0.69) | (2.51) | (0.93) | (0.93) | — |
Net Current Asset Value |
34.46 | 49.03 | 68.27 | 80.01 | 153.00 | (94.56) | (58.98) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.00 | 0.32 | 0.00 | 0.07 | 0.25 | 1.32 | 1.93 | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.61 | 0.64 | 0.53 | 0.41 | 0.32 | 0.42 | 0.46 | — |
Cash ROIC |
(14.03%) | (19.95%) | (14.40%) | (20.22%) | (13.70%) | 291.96% | (64.94%) | — |
Accounts Receivable Turnover |
599.29 | 0.90 | 43.05 | 2.29 | 2.66 | 0.69 | 0.47 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
0.01 | 0.12 | 0.42 | 4.06 | 3.82 | 1.02 | 1.02 | — |
Average Payables |
3.56 | 3.67 | 3.38 | 3.49 | 2.57 | 1.26 | 1.26 | — |
Average Assets |
83.77 | 102.50 | 134.06 | 170.96 | 136.89 | 95.08 | 52.94 | — |
Average Common Equity |
42.94 | 60.54 | 76.82 | 119.82 | 33.58 | (73.20) | (73.20) | — |
Columns are period end dates